Factors in Selecting First-Line Therapy for Patients With Advanced RCC

Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Treatment with belzutifan increased the time to disease progression, according to findings from the LITESPARK-005 trial.

Findings from the phase 3 CheckMate 67T trial showed noninferiority of subcutaneous nivolumab when compared with intravenous nivolumab.